成員介紹 » 副校長

World's Best Medicine Scientists, Research.com
Taiwan Ranking: 6 (2021), 7 (2022), 6 (2023)

World’s Top 2% Scientists, published by Stanford University, Taiwan Ranking
Clinical Medicine: 8 (2021), 1 (2022), 3 (2023)
Microbiology: 1 (2021), 1 (2022), 1 (2023)
General & Internal Medicine: 2 (2021), 2 (2022), 1 (2023)
Biomedical Research: 3 (2021), 1 (2022), 1 (2023)

8

Wan TW, Liu YJ, Wang YT, Lin YT, Hsu JC, Tsai JC, Chiu HC, Hsueh PR, Hung WC, Teng LJ. Potentially conjugative plasmids harboring Tn6636, a multidrug-resistant and composite mobile element, in Staphylococcus aureus. J Microbiol Immunol Infect. 2022;55(2):225-233.

9

Jing R, Yang WH, Xiao M, Li Y, Zou GL, Wang CY, Li XW, Xu YC, Hsueh PR. Species identification and antifungal susceptibility testing of Aspergillus strains isolated from patients with otomycosis in northern China. J Microbiol Immunol Infect. 2022;55(2):282-290. (Corresponding author)

10

Tsai YT, Lee YL, Lu MC, Shao PL, Lu PL, Cheng SH, Ko WC, Lin CY, Wu TS, Yen MY, Wang LS, Liu CP, Lee WS, Shi ZY, Chen YS, Wang FD, Tseng SH, Lin CN, Chen YH, Sheng WH, Lee CM, Tang HJ, Lin CY, Chen YH, Hsueh PR. Nationwide surveillance of antimicrobial resistance in invasive isolates of Streptococcus pneumoniae in Taiwan from 2017 to 2019. J Microbiol Immunol Infect. 2022;55(2):215-224. (Corresponding author)

11

Jean SS, Lee YL, Liu PY, Lu MC, Ko WC, Hsueh PR. Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting Gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018. J Microbiol Immunol Infect. 2022;55(3):463-473. (Corresponding author).

12

Liu PY, Ko WC, Lee WS, Lu PL, Chen YH, Cheng SH, Lu MC, Lin CY, Wu TS, Yen MY, Wang LS, Liu CP, Shao PL, Lee YL, Shi ZY, Chen YS, Wang FD, Tseng SH, Lin CN, Chen YH, Sheng WH, Lee CM, Tang HJ, Hsueh PR. In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018-2020. J Microbiol Immunol Infect. 2022;55(5):888-895. (Corresponding author).

13

Wang WY, Chiu CF, Lee YT, Hsueh PR, Tsao SM. Molecular epidemiology and phenotypes of invasive methicillin-resistant vancomycin-intermediate Staphylococcus aureus in Taiwan. J Microbiol Immunol Infect. 2022 ;55(6 Pt 2):1203-1210..

14

Zhou ML, Wang ZR, Li YB, Kudinha T, Wang J, Wang Y, Xiao M, Xu YC, Liu ZY, Hsueh PR. Rapid identification of Streptococcus pneumoniae serotypes by cpsB gene-based sequetyping combined with multiplex PCR. J Microbiol Immunol Infect. 2022;55(5):870-879. (Corresponding author).

15

Jean SS, Ko WC, Lee WS, Lu MC, Hsueh PR; SMART Program. Multicenter surveillance of in vitro activities of cefepime-zidebactam, cefepime-enmetazobactam, omadacycline, eravacycline, and comparator antibiotics against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii complex causing bloodstream infection in Taiwan, 2020. Expert Rev Anti Infect Ther. 2022;20(6):941-953. (Corresponding author).

16

Lee YL, Ko WC, Hsueh PR. Geographic patterns of carbapenem-resistant Pseudomonas aeruginosa in the Asia-Pacific Region: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2015-2019. Antimicrob Agents Chemother. 2022;66(2):e0200021. (Corresponding author).

17

Yeh TK, Jean SS, Lee YL, Lu MC, Ko WC, Lin HJ, Liu PY, Hsueh PR. Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy. Int J Antimicrob Agents. 2022;59:106475. (Corresponding author).

18

Yamano Y, Ishibashi N, Kuroiwa M, Takemura M, Sheng WH, Hsueh PR. Characterization of cefiderocol-non-susceptible Acinetobacter baumannii isolates from Taiwan. J Glob Antimicrob Resist. 2022;28:120-4. (Corresponding author).

19

Huang YT, Kuo YW, Lee NY, Tien N, Liao CH, Teng LJ, Ko WC, Hsueh PR; SMART study group. Evaluating NG-Test CARBA 5 Multiplex immunochromatographic and Cepheid Xpert CARBA-R assays among carbapenem-Resistant Enterobacterales isolates associated with bloodstream infection. Microbiol Spectr. 2022;10(1):e0172821. (Corresponding author).

20

Wang WY, Hsueh PR, Tsao SM; TIST study group. Genotyping of methicillin-resistant Staphylococcus aureus isolates causing invasive infections using spa typing and their correlation with antibiotic susceptibility. Int J Antimicrob Agents. 2022 59(3):106525.

21

Lee YL, Chen HM, Hii IM, Hsueh PR. Carbapenemase-producing Enterobacterales infections: Recent advances in diagnosis and treatment. Int J Antimicrob Agents. 2022;59(2):106528. (Corresponding author).

22

Jean SS, Lu MC, Ho MW, Ko WC, Hsueh PR; SMART Taiwan Group. Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019. Int J Antimicrob Agents. 2022;59(3):106521. (Corresponding author).

23

Lin YT, Hung WC, Wan TW, Li H, Lee TF, Hsueh PR, Teng LJ. Staphylococcus taiwanensis sp. nov., isolated from human blood. Int J Syst Evol Microbiol. 2022 ;72(2).  

24

Tseng YC, Lin PB, Hsiao CT, Hsueh PR. Multiplex PCR rapid testing for meningitis/encephalitis. J Infect. 2022;84(6):834-872. (Corresponding author).

25

Jean SS, Harnod D, Hsueh PR. Global threat of carbapenem-resistant Gram-negative bacteria. Front Cell Infect Microbiol. 2022;12:823684. (Corresponding author).

26

Liao CH, Huang YT, Hsueh PR. Multicenter surveillance of capsular serotypes, virulence genes, and antimicrobial susceptibilities of Klebsiella pneumoniae causing bacteremia in Taiwan, 2017-2019. Front Microbiol. 2022;13:783523. (Corresponding author).

27

Wu PH, Chen CH, Chou CH, Ho MW, Liu YH, Lin HH, Chen KF, Hsueh PR. FilmArray Meningitis/Encephalitis (M/E) false-negative for cryptococcal meningitis. J Infect. 2022;85(1):90-122.  (Corresponding author).

28

Kang CM, Lee NY, Lin CH, Hsu YS, Chang YC, Chung MY, Lee YF, Tseng WP, Wu JL, Chen SY, Lu MC, Ko WC, Lee PI, Hsueh PR. Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan. J Clin Virol. 2022;150-151:105156. (Corresponding author).

29

Antimycobacterial Susceptibility Testing Group; Antimycobacterial Susceptibility Testing Group: Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. Eur Respir J. 2022;59(4):2200166. 

30

Yoshida M, Chien JY, Morimoto K, Kinjo T, Aono A, Murase Y, Fujiwara K, Morishige Y, Nagano H, Jou R, Hasegawa N, Ato M, Hoshino Y, Hsueh PR, Mitarai S. molecular epidemiological characteristics of mycobacterium abscessus complex derived from non-cystic fibrosis patients in Japan and Taiwan. Microbiol Spectr. 2022;10(3):e0057122. (Corresponding author).

31

Tien N, Chang YC, Chen PK, Lin HJ, Chang SH, Lan JL, Hsueh PR, Chang CK, Chen DY. The immunogenicity and safety of three types of SARS-CoV-2 vaccines in adult patients with immune-mediated inflammatory diseases: a longitudinal cohort study. Biomedicines. 2022;10(4):911.

32

Jean SS, Lee YL, Hsu CW, Hsueh PR. In vitro susceptibilities of isolates of potentially naturally inducible chromosomal AmpC-producing metallo-β-lactamase-negative carbapenem-resistant Enterobacterales species to ceftazidime-avibactam: Data from the Antimicrobial Testing Leadership and Surveillance Programme, 2012-2019. Int J Antimicrob Agents. 2022;60(3):106617. (Corresponding author).

33

Yen MY, Schwartz J, Hsueh PR. The implications of the COVID-19 pandemic for long term care facilities. Curr Opin Infect Dis. 2022;35(4):370-377. 

34

Chien JY, Yu CJ, Hsueh PR. Utility of metagenomic next-generation sequencing for etiological diagnosis of patients with sepsis in intensive care units. Microbiol Spectr. 2022 ;10(4):e0074622. (Corresponding author).

35

Lee JC, Lee CC, Chiu CW, Tsai PJ, Hsueh PR, Lee YT, Hung YP, Ko WC. Reappraisal of the clinical role of metronidazole therapy for Clostridioides difficile infection in Taiwan: A multicenter prospective study. .J Formos Med Assoc. 2022;121(12):2608-2616.

36

Huang YM, Lu CH, Cheng CF, Shen CY, Hsieh SC, Li KJ, Chien JY, Hsueh PR; TACTICS Study Group. Clinical features and prognostic predictors in patients with rheumatic diseases complicated by Pneumocystis pneumonia. Int J Infect Dis. 2022;122:1018-1025. 

37

Yeh TK, Lin HJ, Liu PY, Wang JH, Hsueh PR. Antibiotic resistance in Enterobacter hormaechei. Int J Antimicrob Agents. 2022;60(4):106650. (Corresponding author).

38

Chang YC, Hsiao CT, Chen WL, Su YD, Hsueh PR. BioFire FilmArray Respiratory Panel RP2.1 for SARS-CoV-2 detection: The pitfalls. J Infect. 2022;85(5):e149-e151. (Corresponding author).

39

Chen HF, Hsueh PR, Liu YY, Chen Y, Chang SY, Wang WJ, Wu CS, Tsai YM, Liu YS, Su WC, Chou YC, Hung MC. Disulfiram blocked cell entry of SARS-CoV-2 via inhibiting the interaction of spike protein and ACE2. Am J Cancer Res. 2022;12(7):3333-3346. (Co-first author)

40

Lai CC, Hsu CK, Yen MY, Lee PI, Ko WC, Hsueh PR. Monkeypox: An emerging global threat during the COVID-19 pandemic. J Microbiol Immunol Infect. 2022;55(5):787-794. (Corresponding author).

41

Lin HH, Tseng KH, Tien N, Lin YT, Yu J, Hsueh PR, Cho DY. Evaluation of the Rapid Sepsityper protocol and specific MBT-Sepsityper module for the identification of bacteremia and fungemia using Bruker Biotyper MALDI-TOF MS. J Microbiol Immunol Infect. 2022;55(6):1330-1333. (Corresponding author).

42

Hung YP, Lee CC, Lee JC, Chiu CW, Hsueh PR, Ko WC. A brief on new waves of monkeypox and vaccines and antiviral drugs for monkeypox. J Microbiol Immunol Infect. 2022;55(5):795-802.

43

Lee JA, Lee TF, Huang YT, Hsueh PR. Catheter-related bloodstream infection due to Bordetella trematum. J Infect. 2022;85(6):e175-e176. (Corresponding author).

44

Lee YL, Ko WC, Hsueh PR. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020. Int J Antimicrob Agents. 2022;60(5-6):106679. (Corresponding author).

45

Jean SS, Yang HJ, Hsieh PC, Huang YT, Ko WC, Hsueh PR. In Vitro Susceptibilities of worldwide isolates of intrapulmonary Aspergillus species and important Candida species in sterile body sites against important antifungals: Data from the Antimicrobial Testing Leadership and Surveillance Program, 2017-2020. Microbiol Spectr. 2022;10(6):e0296522. (Corresponding author)..  

46

Chen XF, Zhang H, Jia XM, Cao J, Li L, Hu XL, Li N, Xiao YL, Xia F, Ye LY, Hu QF, Wu XL, Ning LP, Hsueh PR, Fan X, Yu SY, Huang JJ, Xie XL, Yang WH, Li YX, Zhang G, Zhang JJ, Duan SM, Kang W, Wang T, Li J, Xiao M, Hou X, Xu YC. Antifungal susceptibility profiles and drug resistance mechanisms of clinical Candida duobushaemulonii isolates from China. Front Microbiol. 2022;13:1001845. 

47

Lee TF, Lin KY, Chang SY, Huang YT, Hsueh PR. Performance of two commercial multiplex polymerase chain reaction assays for the etiological diagnosis of sexually transmitted infections among men who have sex with men. J Microbiol Immunol Infect. 2023;56(1):104-110. (Corresponding author).

48

Lai CC, Hsu CK, Hsueh SC, Yen MY, Ko WC, Hsueh PR. Multisystem inflammatory syndrome in adults: Characteristics, treatment, and outcomes. J Med Virol. 2023 95(2):e28426. (Corresponding author).

49

Yu J, Lin HH, Tseng KH, Tien N, Hsueh PR, Cho DY. Direct prediction of ceftazidime-resistant Stenotrophomonas maltophilia from routine MALDI-TOF mass spectra using machine learning. J Infect. 2023;86(2):e58-e60. (Corresponding author).

50

Wan TW, Yeo HH, Lee TF, Huang YT, Hsueh PR, Chiu HC. Molecular epidemiology of bacteraemic vancomycin-resistant Enterococcus faecium isolates and in vitro activities of SC5005 and other comparators against these isolates collected from a medical centre in northern Taiwan, 2019-2020. J Antimicrob Chemother. 2023;78(2):457-465.

51

Lai CC, Hsueh PR. Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment. J Med Virol. 2023;95(2):e28430. (Corresponding author).

52

Park SH, Hong SH, Kim K, Lee SW, Yon DK, Jung SJ, Abdeen Z, Brahim Ahmed MLC, Serouri AA, Al-Herz W, Subbaram K, Shaik Syed P, Ali S, Ali K, Al-Shamsi HO, Baatarkhuu O, Nielsen HB, Bernini-Carri E, Bondarenko A, Cassell A, Cham A, Chua ML, Dadabhai S, Darre T, Davtyan H, Dragioti E, East B, Jeffrey Edwards R, Ferioli M, Georgiev T, Ghandour L, Harapan H, Hsueh PR, Ikram A, Inoue S, Jacob L, Janković S, Jayarajah U, Jesenak M, Kakodkar P, Kapata N, Kebede Y, Khader Y, Kifle M, Koh D, Maleš VK, Kotfis K, Koyanagi A, Kretchy JP, Lakoh S, Lee J, Lee JY, Mendonça MDLL, Ling L, Llibre-Guerra J, Machida M, Makurumidze R, Mallah S, Memish ZA, Mendoza I, Moiseev S, Nadasdy T, Nahshon C, Ñamendys-Silva SA, Yongsi BN, Nicolasora AD, Nugmanova Z, Oh H, Oksanen A, Owopetu O, Ozguler ZO, Perez GE, Pongpirul K, Rademaker M, Radojevic N, Roca A, Rodriguez-Morales AJ, Viveiros Rosa SG, Roshi E, Saeed KMI, Sah R, Sakakushev B, Sallam DE, Sathian B, Schober P, Simonović Z, Singhal T, Skhvitaridze N, Solmi M, Tizaoui K, Tlhakanelo JT, Torales J, Torres-Roman S, Tsartsalis D, Tsolmon J, Vieira DN, Wanghi G, Wollina U, Xu RH, Yang L, Zia K, Zildzic M, Il Shin J, Smith L. Non-Pharmaceutical Interventions Reduce the Incidence, and Mortality of COVID-19: A Study based on the Survey from the International COVID-19 Research Network (ICRN). J Med Virol. 2023;95(2):e28354.

53

Lai CC, Hsu CK, Yen MY, Lee PI, Ko WC, Hsueh PR. Long COVID: An inevitable sequela of SARS-CoV-2 infection. J Microbiol Immunol Infect. 2023;56(1):1-9. (Corresponding author).

54

Lee YL, Ko WC, Hsueh PR. Geographic patterns of Acinetobacter baumannii and carbapenem resistance in the Asia-Pacific Region: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2019. Int J Infect Dis. 2023;127:48-55.  (Corresponding author).

55

Lee JA, Du SH, Lee TF, Huang YS, Liao CH, Huang YT, Hsueh PR. Rapid emergence of ceftazidime-avibactam resistance among carbapenem-resistant Enterobacterales in a tertiary-care hospital in Taiwan. J Infect. 2023;86(1):66-117. (Corresponding author).

56

Teo KF, Chen DY, Hsu JT, Lai YH, Chang CK, Hsueh PR, Lan JL, Hsu JL. Screening and characterization of myositis-related autoantibodies in COVID-19 patients. Clin Transl Sci. 2023;16(1):140-150.

57

Liu YM, Ko WC, Ho MW, Lee YL, Hsueh PR. In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Pseudomonas aeruginosa in Taiwan: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) in 2020. J Infect. 2023;86(1):66-117. (Corresponding author).

58

Chen CH, Wu PH, Lu MC, Ho MW, Hsueh PR. Geographic patterns of carbapenem-resistant, multidrug-resistant, and difficult-to-treat Acinetobacter baumannii in the Asia-Pacific Region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020. Int J Antimicrob Agents. 2023;61(2):106707. (Corresponding author).

59

Hazam PK, Cheng CC, Lin WC, Hsieh CY, Hsu PH, Chen YR, Li CC, Hsueh PR, Chen JY. Strategic modification of low-activity natural antimicrobial peptides confers antibacterial potential in vitro and in vivo. Eur J Med Chem. 2023;249:115131.

60

Wu PH, Chen CH, Lin YT, Ao Y, Lin KH, Hsih WH, Chou CH, Chi CY, Ho MW, Hsueh PR. Cryptococcus tetragattii meningitis associated with travel, Taiwan. Emerg Infect Dis. 2023;29(2):447-448. (Corresponding author).

61

Lee PI, Hsueh PR. Multisystem inflammatory syndrome in children: A dysregulated auto immune disorder following COVID-19. J Microbiol Immunol Infect. 2023;56(2):236-245.

62

Chen CH, Wu PH, Lu MC, Ho MW, Hsueh PR; SMART Programme Study Group. National surveillance of antimicrobial susceptibilities to ceftaroline, dalbavancin, telavancin, tedizolid, eravacycline, omadacycline, and other comparator antibiotics and genetic characteristics of bacteremic Staphylococcus aureus isolates in adults: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) programme in 2020. Int J Antimicrob Agents. 2023;61(4):106745. (Corresponding author).

63

Wang HT, Bai LY, Wang YT, Lin HJ, Yang HR, Hsueh PR, Cho DY. Circulating tumor cells positivity provides an early detection of recurrence of pancreatic cancer. J Formos Med Assoc. 2023;122(7):653-655. (Corresponding author).

64

Jean SS, Liu IM, Hsieh PC, Kuo DH, Liu YL, Hsueh PR. Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria. Int J Antimicrob Agents. 2023;61(5):106763. (Corresponding author).

65

Wen LL, Kuo PY, Thuy TTD, Duong TTT, Huang YT, Hsueh PR, Chen YC, Kao CY. Genome-based characterization of conjugative IncHI1B plasmid carrying carbapenemase genes blaVIM-1, blaIMP-23, and truncated blaOXA-256 in Klebsiella pneumoniae NTU107224. Infect Genet Evol. 2023;110:105420.

66

Chang TH, Hsueh PR, Huang YT, Chen PY, Tang HJ, Chen JM. Prolonged Streptococcus gallolyticus subsp. pasteurianus gut colonization in healthcare workers and potential transmission role in neonatal sepsis. J Microbiol Immunol Infect. 2023;56(3):605-611.

67

Yang TY, Tseng SP, Ho HC, Chen LH, Hsueh PR, Lu PL, Lin CH, Wang LC. In vitro evaluation of tellurium-based AS101 compound against Neisseria gonorrhoeae infectivity. Microbiol Spectr. 2023;11(2):e0149622

68

Yu ZY, Lai CF, Lai TS, Yang SY, Chen SI, Lai MJ, Kang CM, Huang YT, Chen YT, Hsueh PR, Chen YM, Lin SL. Humeral and cellular immune responses to SARS-CoV-2 vaccination in patients on peritoneal dialysis. J Formos Med Assoc. 2023;122(9):922-931. 

69

Wu PH, Chen CH, Hsih WH, Chou CH, Chi CY, Ho MW, Lin YT, Lin HH, Tseng KH, Hsueh PR. Emergence of meropenem and levofloxacin resistance in Burkholderia pseudomallei in Taiwan. J Infect. 2023;86(6):e161-e163. (Corresponding author).

70

Yu JX, Lin YT, Chen WC, Tseng KH, Lin HH, Tien N, Cho CF, Huang JY, Liang SJ, Ho LC, Hsieh YW, Hsu KC, Ho MW, Hsueh PR, Cho DY. Direct prediction of carbapenem-resistant, carbapenemase-producing, and colistin-resistant Klebsiella pneumoniae isolates from routine MALDI-TOF mass spectra using machine learning and outcome evaluation. Int J Antimicrob Agents. 2023;61(6):106799. (Corresponding author).

71

Chang CY, Lee YL, Huang YT, Ko WC, Ho MW, Hsueh PR. In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020. Int J Antimicrob Agents. 2023;61(6):106815. (Corresponding author).

72

Cheng NC, Cheng Y, Tai HC, Chien KL, Wang SH, Chen YH, Fang CT, Hsueh PR. High mortality risk of type iii monomicrobial Gram-negative necrotizing fasciitis: the role of extraintestinal pathogenic Escherichia coli (ExPEC) and Klebsiella pneumoniae. Int J Infect Dis. 2023;132:64-71. (Co-Corresponding author).

73

Lai CC, Lee PI, Hsueh PR. How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020-2022. J Microbiol Immunol Infect. 2023;56(3):433-441. (Corresponding author).

74

Kao CH, Liu YH, Chen WK, Huang FW, Hsu TY, Cheng HT, Hsueh PR, Hsiao CT, Wu SY, Shih HM. Value of monocyte distribution width for predicting severe cholecystitis: a retrospective cohort study. Clin Chem Lab Med. 2023 ;61(10):1850-1857.

75

Shie MY, Fang HY, Kan KW, Ho CC, Tu CY, Lee PC, Hsueh PR, Chen CH, Lee AK, Tien N, Chen JX, Shen YC, Chang JG, Shen YF, Lin TJ, Wang B, Hung MC, Cho DY, Chen YW. Highly mimetic ex vivo lung-cancer spheroid-based physiological model for clinical precision therapeutics. Adv Sci (Weinh). 2023;10(16):e2206603.

76

Wu PH, Chen CH, Lin HH, Tseng KH, Ko WC, Ho MW, Hsueh PR. Geographic patterns of antimicrobial susceptibilities for Bacteroides species worldwide: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2007-2020. Int J Antimicrob Agents. 2023;62(1):106822. (Corresponding author).

77

Lee YL, Hsueh PR. Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021. J Infect. 2023;87(1):e1-e4. (Corresponding author).

78

Hao X, Shen Y, Chen N, Zhang W, Valverde E, Wu L, Chan HL, Xu Z, Yu L, Gao Y, Bado I, Michie LN, Rivas CH, Dominguez LB, Aguirre S, Pingel BC, Wu YH, Liu F, Ding Y, Edwards DG, Liu J, Alexander A, Ueno NT, Hsueh PR, Tu CY, Liu LC, Chen SH, Hung MC, Lim B, Zhang XH. Osteoprogenitor-GMP crosstalk underpins solid tumor-induced systemic immunosuppression and persists after tumor removal. Cell Stem Cell. 2023;30(5):648-664.e8. 

79

Lai CC, Hsueh PR. Beyond mental stress-induced myocardial ischemia following the COVID-19 vaccine. Biomedicine (Taipei). 2023;13(1):1-2. (Corresponding author).

80

Lee YL, Ko WC, Hsueh PR. In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021. Int J Antimicrob Agents. 2023;62(2):106867. (Corresponding author).

81

Chang YH, Hsiao CT, Chang YC, Lai HY, Lin HH, Chen CC, Hsu LC, Wu SY, Shih HM, Hsueh PR, Cho DY. Machine learning of cell population data, complete blood count, and differential count parameters for early prediction of bacteremia among adult patients with suspected bacterial infections and blood culture sampling in emergency departments. J Microbiol Immunol Infect. 2023;56(4):782-792. (Corresponding author).

82

Lee YL, Liu CE, Ko WC, Hsueh PR. In vitro susceptibilities of Stenotrophomonas maltophilia isolates to antimicrobial agents commonly used for related Infections: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2004-2020. Int J Antimicrob Agents. 2023;62(2):106878. (Corresponding author).

83

Chen XJ, Wan TW, Chao QT, Teng LJ, Lee TF, Huang YT, Hsueh PR. Applicability of an in-house extraction protocol in a Bruker Biotyper matrix-assisted laser desorption/ionization time-of-flight mass spectrometry system for the identification of Streptococcus agalactiae from broth-enriched vaginal/rectal swab specimens. J Microbiol Immunol Infect. 2023;56(4):815-821. (Corresponding author).

84

Su HC, Lai ZL, Chang YC, Cheng MY, Hsih WH, Chen YJ, Chou CH, Chen CL, Lin YC, Lin TH, Hsiao CT, Ho MW, Shih HM, Hsueh PR, Cho DY. Genomic characteristics of SARS-CoV-2 variants and their clinical impact on patients with COVID-19 in Taiwan. J Infect. 2023;87(3):263-266. (Corresponding author).

85

Mei ZX, Han JF, Yu HW, Zhang Y, Ji P, Xie Y, Hsueh PR. Detection of serum Aspergillus-specific IgM and IgG antibody levels for the diagnosis of chronic pulmonary aspergillosis developed in patients with tuberculosis. Eur J Clin Microbiol Infect Dis. 2023; 42(9):1081-1089. (Corresponding author).

86

Wang JL, Lai CC, Ko WC, Hsueh PR. Geographic patterns of in vitro susceptibilities to tigecycline and colistin among worldwide isolates of Acinetobacter baumannii, Escherichia coli and Klebsiella pneumoniae: data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2016 to 2021. Int J Antimicrob Agents. 2023;62(3):106930. (Corresponding author).

87

Lee YL, Hsueh PR. Emerging infections in vulnerable hosts: Stenotrophomonas maltophilia and Elizabethkingia anophelis. Curr Opin Infect Dis. 2023;36(6):481-494. (Corresponding author).

88

Chen IR, Wang GJ, Hsueh PR, Chou CH, Jeng LB, Lin HJ, Liao HJ, Lai PC, Chang JG, Huang CC. Immune responses and safety of COVID-19 vaccination in atypical hemolytic uremic syndrome patients in Taiwan. Vaccine. 2023;41(41):5940-5945.

89

Hsueh PR, Ho SJ, Hsieh PC, Liu IM, Jean SS. use of multiple doses of intravenous infusion of umbilical cord-mesenchymal stem cells for the treatment of adult patients with severe COVID-19-related acute respiratory distress syndrome: literature review. Stem Cells Int. 2023;2023:7179592.

90

Chen HF, Wang WJ, Chen CY, Chang WC, Hsueh PR, Peng SL, Wu CS, Chen Y, Huang HY, Shen WJ, Wang SC, Hung MC The natural tannins oligomeric proanthocyanidins and punicalagin are potent inhibitors of infection by SARS-CoV-2. Elife. 2023;12:e84899.

91

Tseng PT, Zeng BS, Thompson T, Stubbs B, Hsueh PR, Su KP, Chen YW, Chen TY, Wu YC, Lin PY, Carvalho AF, Hsu CW, Li DJ, Yeh TC, Sun CK, Cheng YS, Shiue YL, Liang CS, Tu YK. Placebo effects on all-cause mortality of COVID-19 patients in randomized controlled trials of interleukin-6 antagonists: a systematic review and network meta-analysis. Psychiatry Clin Neurosci. 2023;77(12):638-645.

92

Cheng WJ, Shih HM, Su KP, Hsueh PR. Risk factors for poor COVID-19 outcomes in patients with psychiatric disorders. Brain Behav Immun. 2023;114:255-261.

93

Chang CL, Yu CJ, Hsueh PR, Chien JY. Treatment outcomes and relapse in patients with Mycobacterium avium-intracellulare complex pulmonary disease. Microbiol Spectr. 2023;11(5):e0164023.

94

Yu J, Lin HH, Tseng KH, Lin YT, Chen WC, Tien N, Cho CF, Liang SJ, Ho LC, Hsieh YW, Hsu KC, Ho MW, Hsueh PR, Cho DY. Prediction of methicillin-resistant Staphylococcus aureus and carbapenem-resistant Klebsiella pneumoniae from flagged blood cultures by combining rapid Sepsityper MALDI-TOF mass spectra with machine learning. Int J Antimicrob Agents. 2023;62(6):106994. (Corresponding author).

95

Su Y-D, Lai C-C, Lin T-H, Chen W-C, Hsueh P-R. Performance evaluation of the cobas SARS-CoV-2 Duo, a novel qualitative and quantitative assay, for the detection of SARS-CoV-2 RNA. Microbiol Spectr. 2023:e0136923. (Corresponding author).

96

Chen CH, Low YY, Liu YH, Lin HH, Ho MW, Hsueh PR. Rapid detection of gastrointestinal pathogens using a multiplex polymerase chain reaction gastrointestinal panel and its role in antimicrobial stewardship. J Microbiol Immunol Infect. 2023;56(6):1273-1283. (Corresponding author).

97

Xiao LY, Su YL, Huang SY, Chen YH, Hsueh PR. Chitinase 3-like-1 expression in the microenvironment is associated with neutrophil infiltration in bladder cancer. Int J Mol Sci. 2023;24(21):15990. (Corresponding author).

98

Wu CS, Li YC, Peng SL, Chen CY, Chen HF, Hsueh PR, Wang WJ, Liu YY, Jiang CL, Chang WC, Wang SC, Hung MC. Coffee as a dietary strategy to prevent SARS-CoV-2 infection. Cell Biosci. 2023;13(1):210.

99

Tseng PT, Zeng BS, Hsu CW, Thompson T, Stubbs B, Hsueh PR, Su KP, Chen YW, Chen TY, Wu YC, Lin PY, Carvalho AF, Li DJ, Yeh TC, Sun CK, Cheng YS, Shiue YL, Liang CS, Tu YK. The difference in all-cause mortality between COVID-19 patients treated with standard of care plus placebo and those treated with standard of care alone: a network meta-analysis of randomised controlled trials of immunomodulatory kinase inhibitors. J R Soc Med. 2023 Nov 16:1410768231202657.

100

Wan TW, Lee TF, Chen XJ, Hunag YT, Teng LJ, Hsueh PR, Chiu HC. J. Performance assessment of the Bruker Biotyper MALDI-TOF MS for the identification of difficult-to-identify viridans group streptococci. J Clin Microbiol. 2023;61(12):e0114323. (Corresponding author).

101

Chang HC, Su TH, Huang YT, Hong CM, Sheng WH, Hsueh PR, Kao JH. Liver dysfunction and clinical outcomes of unvaccinated COVID-19 patients with and without chronic hepatitis B. J Microbiol Immunol Infect 2023 Dec 2:S1684-1182(23)00209-8.

102

Chen CL, Lin YC, Tseng HY, Chen WC, Liang SJ, Tu CY, Hsueh PR. High mortality of patients with severe pneumonia caused by respiratory syncytial virus, August 2021-June 2023, Taiwan. J Microbiol Immunol Infect. 2023 Dec 21. (Corresponding author).

103

Cheng WJ, Shih HM, Su KP, Hsueh PR. Reply to letter by Dr. Fu and Dr. Chu: Risk factors for poor COVID-19 outcomes in patients with psychiatric disorders. Brain Behav Immun. 2024;115:448-449.

104

Yii YC, Shih HM, Chen CL, Lai ZL, Hsu YL, Lai CH, Hsueh PR, Cho DY. Impact of pre-hospitalization use of oral antiviral agents on reducing critical illness and mortality for patients with COVID-19 pneumonia. Int J Antimicrob Agents. 2024;63(1):107020. (Corresponding author).

105

Liao TY, Huang YT, Lee TF, Hsueh PR, Yu CJ, Chien JY. Clinical significances of mutations in dihydropteroate synthase in Pneumocystis jirovecii pneumonia among non-HIV-infected patients. Int J Antimicrob Agents. 2024;63(1):107019.

106

Wang JL, Lai CC, Ko WC, Hsueh PR. Global trends in nonsusceptibility rates of Streptococcus pneumoniae isolates to ceftriaxone: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2016-21. Int J Antimicrob Agents. 2023;63(2):107072. (Corresponding author).

107

Jean SS, Liu CY, Huang YT, Ko WC, Ho MW, Liu IM, Hsieh PC, Hsueh PR. Minimum inhibitory concentrations of antifungals against invasive isolates of Cryptococcus species worldwide: global antifungal Antimicrobial Testing Leadership and Surveillance Program, 2010-2020. Int J Antimicrob Agents. 2024 Jan 17:107090. (Corresponding author).